research Folliculitis decalvans associated with erlotinib
Erlotinib can cause hair loss and scalp issues, which improve after stopping the drug.
Search
for
Sort by
Research
930-960 / 1000+ results
research Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model
50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.
research EFFECT OF "AMINOPTERIN" ON EPITHELIAL TISSUES
Aminopterin strongly suppresses epithelial tissues and can treat certain skin conditions but has significant side effects.
research Alopecia areata as an immune-related adverse event associated with response to immune checkpoint inhibitors
research Functional Interpretation of Genome-Wide Association Study Evidence in Alopecia Areata
Alopecia areata is linked to immune-related genes, suggesting JAK inhibitors as a potential treatment.
research EFFECT OF "AMINOPTERIN" ON EPITHELIAL TISSUES
Aminopterin effectively improves skin conditions but has toxic side effects that need careful monitoring.
research Epidermal growth factor receptor inhibitor Geftinib-induced erosive pustular dermatosis of the scalp – A report with a brief review of the literature
Gefitinib can cause scalp skin issues and permanent hair loss.
research Ixekizumab improves physical function, quality of life, and work productivity in biologic disease-modifying antirheumatic drug-naive patients with active psoriatic arthritis
Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
research Predictors and Management of Inadequate Response to JAK Inhibitors in Alopecia Areata
Switching JAK inhibitors or using dupilumab may help some alopecia areata patients who don't respond well to initial treatments.
research Delayed granulomatous eruption of the nose associated with ruxolitinib
Ruxolitinib can cause a delayed skin reaction on the nose.
research Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
Baricitinib was effective in treating a patient with dermatomyositis and hair loss.
research Characteristics and predictive values of super-responders in alopecia areata under tofacitinib treatment: A single-center retrospective study
Older patients without prior JAK inhibitor treatment respond best to tofacitinib for alopecia areata.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
research Prevention of erlotinib-induced folliculitis with doxycycline
Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.
research Baricitinib (Olumiant)
Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
research EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
Early diagnosis and treatment of EGFR inhibitor-induced folliculitis decalvans can prevent permanent hair loss.
research Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management
Selumetinib causes skin and hair side effects in kids with NF1, affecting treatment and quality of life.
research Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
research Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata
SCD-153 shows promise as an effective topical treatment for alopecia areata.
research 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials
Baricitinib helps regrow hair and improves quality of life and mental health in severe alopecia areata patients.
research Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
Skin side effects from cancer drugs targeting EGFR can affect treatment adherence but can be managed with antibiotics like tetracycline.
research Scanning electron microscopy of ibrutinib-induced hair shaft changes
research 1409 Temporary cell cycle arrest by ALRN-6924: A novel, p53-targeting strategy to protect human scalp hair follicles against cyclophosphamide-induced alopecia
ALRN-6924 can protect hair follicles from chemotherapy damage by temporarily stopping cell division.
research New drugs under investigation for the treatment of alopecias
New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
research Evaluation of Therapeutic Potential of a Selective 5α-reductase Inhibitor against Glioblastoma: Molecular Docking and In Vitro Insights
research Spironolactone, a Classic Potassium-Sparing Diuretic, Reduces Survivin Expression and Chemosensitizes Cancer Cells to Non-DNA-Damaging Anticancer Drugs
Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
research Down‐regulation of Shh in the hair follicles of mice during chemotherapy‐induced hair loss is mediated by the JAK / STAT1 signaling pathway
JAK/STAT1 pathway causes hair loss during chemotherapy by reducing Shh in hair follicles.
research The use of topical ruxolitinib 1.5% cream in frontal fibrosing alopecia: A case report
Topical ruxolitinib cream may help treat frontal fibrosing alopecia.
research Treatment of moderate-to-severe alopecia areata in patients over the age of 65 with baricitinib
Baricitinib helps treat severe hair loss in people over 65.